RPG Life Sciences Limited has informed the Exchange about Investor Presentation
L
RPG LIFE SCIENCES
October 19, 2023
To
RPG LIFE SCIENCES LIMITED Regd. Off.: RPG House 463, Dr. Annie Besant Road Worli, Mumbai 400030, India Tel: +91-22-24981650 / 66606375 Fax: +91-22-24970127 Email: info@rpglifesciences.com www.rpglifesciences.com CIN : L24232MH2007PLC169354
The Manager Listing Department National Stock Exchange of India Limited Exchange Plaza, 5th Floor, Plot No. C-1, G- Block, Sandra - Kurla Complex, Sandra (East) Mumbai - 400 051
BSE Limited Corporate Relationship Department 25, P.J. Towers, Dalal Street, Mumbai 400 001
Symbol: RPGLIFE
Scrip Code: 532983
Dear Sirs,
Sub: Investor Presentation
Please find enclosed herewith a copy of Investor Presentation with respect to Unaudited
Financial Results of the Company for the quarter and half year ended September 30, 2023.
Kindly take the same on record.
Thanking you,
Yours faithfully, For RPG Life Sciences Limited RAJESH RAMESH DigitallysignedbyRAJESH SHIRAMBEKAR
~~~~~~.023.10.1914:47:44
RAMESH SHIRAMBEKAR
Rajesh Shirambekar Head - Legal & Company Secretary
Encl: As above
An «.RPG Company
L
R?G LIFE SCIENCES
An ~» R?Ci Company
Investors’ Presentation H1 FY24
Disclaimer
This presentation may include statements which may constitute forward-looking statements. All statements that address expectations or projections about the future, including, but not limited to, statements about the strategy for growth, business development, market position, expenditures, and financial results, are forward looking statements. Forward looking statements are based on certain assumptions and expectations of future events. The Company cannot guarantee that these assumptions and expectations are accurate or will be realized. The actual results, performance or achievements, could thus differ materially from those projected in any such forward-looking statements.
The company operates in the Pharmaceutical segment. Some of the historical Profit and loss numbers which are sliced in the investor presentation for certain sales divisions are purely for broader understanding for investors of the business of the company and its growth trajectory. The information contained in these materials has not been independently verified. None of the Company, its Directors, Promoter or affiliates, nor any of its or their respective employees, advisers or representatives or any other person accepts any responsibility or liability whatsoever, whether arising in tort, contract or otherwise, for any errors, omissions or inaccuracies in such information or opinions or for any loss, cost or damage suffered or incurred howsoever arising, directly or indirectly, from any use of this document or its contents or otherwise in connection with this document, and makes no representation or warranty, express or implied, for the contents of this document including its accuracy, fairness, completeness or verification or for any other statement made or purported to be made by any of them, or on behalf of them, and nothing in this document or at this presentation shall be relied upon as a promise or representation in this respect, whether as to the past or the future. The information and opinions contained in this presentation are current, and if not stated otherwise, as of the date of this presentation. The Company undertake no obligation to update or revise any information or the opinions expressed in this presentation as a result of new information, future events or otherwise. Any opinions or information expressed in this presentation are subject to change without notice.
This presentation does not constitute or form part of any offer or invitation or inducement to sell or issue, or any solicitation of any offer to purchase or subscribe for, any securities of RPG Life Sciences Limited Limited (the “Company”), nor shall it or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any contract or commitment, therefore. Any person/ party intending to provide finance / invest in the shares/businesses of the Company shall do so after seeking their own professional advice and after carrying out their own due diligence procedure to ensure that they are making an informed decision. This presentation is strictly confidential and may not be copied or disseminated, in whole or in part, and in any manner or for any purpose. No person is authorized to give any information or to make any representation not contained in or inconsistent with this presentation and if given or made, such information or representation must not be relied upon as having been authorized by any person. Failure to comply with this restriction may constitute a violation of the applicable securities laws. The distribution of this document in certain jurisdictions may be restricted by law and persons into whose possession this presentation comes should inform themselves about and observe any such restrictions. By participating in this presentation or by accepting any copy of the slides presented, you agree to be bound by the foregoing limitations.
An <.>» R?G Company
2
L
~c:; LIFE SCIENCES
RPG Group: One of India's fastest-growing diversified conglomerates
UNlEASHTALENT TOUCH LIVES OUTPERFORM
AND©
RPG Group has a business history dating back to 1820 AD in banking, textiles, jute, and tea. RPG Enterprises was founded in 1979 and currently operates in various businesses in Infrastructure, Technology, Tyres, Life Sciences, and plantation industries. Formerly known as Searle India, RPG Life Sciences was started as a joint venture with G.D Searle in 1968 and was rechristened to RPG Life Sciences in 1999 with G.D Searle withdrawing its India operations.
100+ years old Business Group |
$4.4 Bn Revenue |
20000+ Employees |
BSE Listed Companies
One of India’s leading tyre Manufacturers
EPC major in infrastructure segments like T&D, Civil, Railways, Oil & Gas
_,,, ZenSar Global Technology Consulting and IT services company
L
R?G LIFE SCIENCES
An Integrated Pharmaceutical company operating in Formulations and Synthetic APIs
Raychem R?G
Technology Solutions company catering to energy and infrastructure
An <.>» R?G Company __________________ _
HMRISONS MJ\L.AYAU\M UM/TED
One of India’s largest plantation companies producing tea, rubber etc
L
~c:; LIFE SCIENCES
RPG Life Sciences: An Integrated Pharmaceutical Company –APIs to Formulations; R&D to Manufacturing to Marketing
RPG Life Sciences, part of RPG Enterprises, is an integrated research based pharmaceutical Company operating in the domestic and international markets in the branded formulations, global generics and synthetic APIs space.
Domestic Formulations (DF)
Develop, manufacture and market branded formulations in India & Nepal
APIs 15%
International Formulations (IF) 19%
Domestic Formulations (DF) 66%
International Formulations (IF)
Develop, manufacture and sell oral solid dosage formulations in the generics and branded generics space across regulated and emerging Markets
APIs
Develop, manufacture and sell high value synthetic APIs in the general therapeutic category
0 ®
Leader in Immunosuppressants
9 Therapies represented by High Equity Brands
50+ Markets Presence
3 Manufacturing Facilities
1200+ Employees
L
~c:; LIFE SCIENCES
An <.>» R?G Company _____________________ _
4
RPG Life Sciences Product Portfolio: Strong ‘Textbook’ brands being augmented by Diligent Life Cycle Management and New Launches in Chronic and Specialty therapies
Domestic Formulations (DF)
Key Therapies
Nephrology
Rheumatology
Oncology
Pain Management
Gastroenterology
Neuropsychiatry
Cardiovascular
Diabetes
Urology
Key Products
Legacy Portfolio r-----.::::.::::.::::=~-=--=--=--=--=-----~ Immunosuppressants
Text Book Brands
Azoran· Azathioprine
Mofetyf Mycophenolate Mofetil
Jlrpimr,ne ME Cyclosporine
•1munotac· Tacrolimus
Azoran· Azathioprine Alda~t~ne·
Spironolactone Lomotif Diphenoxylate HCl eNaMQ.~yn· Naproxen Serenace Haloperidol
l~t·H·6[3M
Disopyramide Phosphate
Specialty ~ ~ Trastuzumab
li(
Adlum.p~·
~
Adalimumab Jvfomab ---... ,-.. Bevacizumab ~ tm!!li Rituximab ilm Tofacitinib __ , ... ...; ... -,,-. lroHigh" Iron Isomaltoside 'i>enb.rV· Denosumab
New Portfolio
Chronic 'NuGlip_tm; Vildagliptin
GliptiN~f Teneligliptin
DPU?.. Dapagliflozin
A~ilta ½ Azelinidipine
·~~!firs( Solifenacin
Life Cycle Management (Existing Products) ~..;st~an'75
~ Aldactone.,-a
s,n,,oioc-~"'i• F-2iloot
'Niijirosyir= +
"ROMILAST;BL
'Tricaj.ne•Atm @
Lomofen"LB "<-""'""'..-........ ~,., .. ,-.... ~
N~.~:::!'f}·~
International Formulations (IF)
Key Products Generics - Azathioprine, Sodium Valproate PR, Nicorandil, Sertraline Branded Generics – Siloxogene, Azoran, Mofetyl, Arpimune ME, Dyzantil, Dipsope
APIs
Key Products APIs - Quinfamide, Azathioprine, Haloperidol, Risperidone, Propantheline Bromide, Nicorandil, Pantoprazole, Diphenoxylate
An <->» R?G Company
5
L
~c:; LIFE SCIENCES
Financial Performance
An <.>» R?G Company
6
L
~c:; LIFE SCIENCES
Journey of RPG Life Sciences
1
2
Process Excellence Product Portfolio, People, Business Processes
Fundamentals Fixation Sales Hygiene, People, Organization
3
Sustainable Profitable Growth Revenues, Volumes, Margins
An <.>» R?G Company
4
Benchmark Performance Profitability, Leverage, Liquidity Ratios
5
Scale-up
L
~c:; LIFE SCIENCES
Q2 FY24 Performance
Revenue from Operations
- - - f
EBITDA & EBITDA Margin
134.8
153.6
Q2 FY23
Q2 FY24
31.0
39.1
~ n a
23.0%
25.5%
Q2 FY24
Q2 FY23
PAT & PAT Margin
- - f
20.0
14.8%
25.9
16.8%
(All figures in Rs. Crores except EPS in Rs.)
PBT & PBT Margin
27.0
20.0%
34.8
22.7%
Q2 FY23
Q2 FY24
_f
EPS
15.6
12.1
Figures in circle are Margins
An <.>» R?G Company ______________ _
Q2 FY23
Q2 FY24
Q2 FY23
Q2 FY24
L
~c:; LIFE SCIENCES
H1 FY24 Performance
Revenue from Operations
- - - f
263.7
301.4
EBITDA & EBITDA Margin
60.0
22.8%
73.2
24.3%
(All figures in Rs. Crores except EPS in Rs.)
PBT & PBT Margin
52.1
19.8%
64.6
21.4%
H1 FY23
H1 FY24
H1 FY23
H1 FY24
H1 FY23
H1 FY24
PAT & PAT Margin
- - f
38.2
14.5%
48.0
15.9%
_f
EPS
29.0
23.1
Figures in circle are Margins
H1 FY23
H1 FY24
H1 FY23
H1 FY24
L
An <.>» R?G Company - - - - - - - - - - - - - - ~c:; LIFE SCIENCES
H1 FY24: 5 Year Trends- Key Financials
(All figures in Rs. Crores except EPS in Rs.)
- - f __ f _ f
Revenue from Operations
EBITDA & EBITDA Margin
PBT & PBT Margin
512.8
440.2
375.6 389.1
330.2
301.4
70.8
59.9
34.4
107.5
89.4
73.2
91.7
73.2
64.6
53.6
41.8
15.1
10.4%
15.9% 18.2%
20.3%
21.0% 24.3%
4.6%
11.1% 13.8%
16.6%
17.9%
21.4%
FY19
FY20
FY21
FY22
FY23 H1 FY24
FY19
FY20
FY21
FY22
FY23 H1 FY24
FY19
FY20
FY21
FY22
FY23 H1 FY24
PAT & PAT Margin
- f
67.6
48.0
51.5
40.0
29.0
10.8
3.3%
7.7%
10.3%
11.7%
13.2% 15.9%
_f
EPS
40.9
31.1
29.0
24.2
17.5
6.5
Figures in circle are Margins
FY19
FY20
FY21
FY22
FY23 H1 FY24
FY19
FY20
FY21
FY22
An <.>» R?G Company _____ Ri>G L1FEsc1ENcEs
FY23 H1 FY24
- L
H1FY24: 5Y Trajectory of Uninterrupted Margins Expansion continues despite Market Challenges EBITDA:10.4% (FY19) to 24.3%(H1 FY24);PBT: 4.6% (FY19) to 21.4%(H1 FY24);PAT: 3.3% (FY19) to 15.9% (H1 FY24)
EBITDA% 24.3% PBT% 21.4% PAT% 15.9%
20.3%
21.0%
16.6%
17.9%
11.7%
13.2%
18.2%
13.8%
10.3%
15.9%
11.1%
7.7%
11.1% 10.4%
9.3%
4.7%
5.9%
3.9%
3.9%
9.8%
8.1%
6.2%
6.0%
0.9%
0.5%
0.2%
0.2%
0.4% 0.4%
0.4%
0.4%
8.7%
4.2%
4.2%
Except H1 FY24, all other margin numbers are Full Year numbers
An <.>» R?G Company
4.6%
3.3%
11
L
~c:; LIFE SCIENCES
H1 FY24: 5 Year Trends- Key Ratios (ROCE, ROE, D/E)
_f
ROCE%
_f
ROE%
Debt/Equity Ratio
- l
28.5% 29.7%
18.5% 20.1%
22.0%
0.22
24.9%
9.7%
20.9%
.111 1 .111 1 I. _
16.4%
6.7%
0.06
0.00
0.01
FY19
FY20
FY21
FY22
FY23
FY19
FY22
FY23
FY20
FY21
FY20
FY21
FY19
FY22
0.00
FY23
Company continues to remain Debt-free
12 An <.>» R?G Company ____ Ri>G L1FEsc1ENcEs
L
H1 FY24: Business Segment-wise Performance
Business Segments
Domestic Formulations (DF)
Domestic Formulations contributed 66% to total sales of H1 FY24 • 16% sales growth driven by both Legacy and New products • Growth consistently higher than the market • New products* contribution improving consistently (currently >25%) on account of new
launches in Specialty & Chronic segments and line extensions of legacy products
• Salesforce productivity consistently improving (currently >5 lakhs) • Business driven by 5 Pillar strategy
APIs 15%
IF 19%
DF 66%
International Formulations (IF)
International Formulations contributed 19% to total sales of H1 FY24 • Robust sales growth of 15% • New Products/Customers/Markets contribution continues to improve (currently ~30%) • Business driven by 4 Pillar strategy
API
API contributed 15% to total sales of H1 FY24 • Growth of 7% • Continuous thrust on new customer development • Business driven by 3 Pillar strategy
An <.>» R?G Company
*Launched FY19 Onwards
13
171.8
199.0
H1 FY23
H1 FY24
49.0
56.3
.,_o/o
o/
H1 FY23
H1 FY24
42.9
46.1
H1 FY23
H1 FY24
L
~c:; LIFE SCIENCES
RPG Life Sciences ICRA Rating Reaffirmed in FY23
Long term rating reaffirmed at A Short term rating reaffirmed at A1
Outlook on long term rating has been retained as Stable
The rating reaffirmation factors:
►
►
Strong brands in the Indian Pharmaceutical Industry Considerable improvement in the operating performance on the back of
• •
Improvement in sales hygiene Cost rationalisation measures adopted since FY20
►
A robust capital structure and strong coverage indicators based on
• Decline in the company’s debt levels • Healthy cash flows • No major debt-funded capital expenditure (capex)
►
Expansion of product portfolio and geographical presence augur well for growth prospects
An <.>» R?G Company
14
L
~c:; LIFE SCIENCES
Business Strategy
An <.>» R?G Company
15
L
~c:; LIFE SCIENCES
Domestic Formulations (DF): Overview and Strategy
• Operating in Mass/Mass-specialty and Specialty segments • Presence in both Acute & Chronic therapy areas • • • Good Customer Coverage - Cardiologists, Diabetologists, Urologists, Nephrologists, Rheumatologists, Oncologists • New Product Launches in New Category – Biosimilars as well as Chronic and Specialty segments
Leading Text Book Brands – Azoran, Aldactone, Lomotil, Naprosyn, Serenace, Norpace Leading player in Immunosuppressant category
Business Strategy: 5 Pillars
5 pillars of profitable Domestic business growth
1
2
3
4
5
Product portfolio rejuvenation by building Chronic & Specialty portfolio with new launches
Strategic brand assets building through life cycle management (new line extensions, customer segments, disease segments, etc.)
Customer coverage deepening in targeted therapies by expanding field force and deploying digital
Sales force effectiveness augmentation by competencies building and productivity enhancement initiatives
An <.>» R?G Company
16
Profitability improvement by Opex control, efficient manufacturing operations, sales hygiene as well as profitable product mix
~c:; LIFE SCIENCES
DF: Diligent implementation of 5 Pillars of Business Strategy yielding results
1
2
3
4
5
Product portfolio rejuvenation
Strategic brand assets building
Customer coverage deepening
Sales force effectiveness augmentation
Profitability improvement
*New Product Contribution
28%
FY23
6%
-
FY19
Rheumatology
Strengthening Presence in • • Oncology Augmented Product Basket in • • • Urology
Cardiology Diabetology
Naprosyn+ becomes the first 50 Cr+ Brand Franchise
Expansion of Target Customer base by 20,000 since FY19
Thrust on Building Mega Brands with a well-crafted Life Cycle Management Strategy for identified Legacy Brands
Year-on-Year consistent customer expansion in Target Therapies/ Specialties
Leveraging Digital to increase customer touchpoints and company/brand recall
Augmentation of Product Basket catering to Target Therapies/Specialties
Monthly Revenue per MR (INR Lakhs)
I
.J,Sales
Expiries (%)
5.5
5.0
4.2
4.2
4.3
3.4
2.9
2.4
2.1
1.5
FY19 FY20 FY21 FY22 FY23
FY19 FY20 FY21 FY22 FY23
Consistent Productivity increase led by • •
Skilling programs Productivity-linked Incentive Structure Consistent Promo support
•
Diligent Management of both OPEX and COGs
Product Re-engineering
*New Launches since FY19
An <.>» R?G Company ____________________ _
L
~c:; LIFE SCIENCES
International Formulations (IF) Business: Overview and Strategy
• Strong presence in immunosuppressant segment (Azathioprine) • Footprints across Regulated and Emerging Markets - Canada, UK, Germany, France, Australia, South East Asia, Africa •
Long lasting, impeccable supply track record and business relationship with some of the leading generic players of the world
• High quality and process orientation making us a preferred partner
Business Strategy: 4 Pillars
3 pillars of step-wise Global business build up
1
2
3
4
Build immunosuppressant portfolio
•
•
Build Pipeline of New products with specific/ competitive advantage with focusses R&D Team Expanded R&D Team
Expand footprints in emerging and select markets
Modernize Infrastructure/ Increase Capacity of Plants (Formulations)
An <.>» R?G Company
18
L
~c:; LIFE SCIENCES
APIs Business: Overview and Strategy
• High value, low volume, niche APIs • Mature stable molecules •
Provides backward integration to International Formulations business
•
•
Footprints across geographies - LATAM, Germany, China, South Korea, Iran, Bangladesh, Egypt, India, etc. Strong customer focus – long-lasting relationship with big pharma and leading generic firms.
Business Strategy: 3 Pillars
Business continuity
1
2
3
Ensure Market/Customer Expansion (Existing Products)
Create a Pipeline of Niche Product/Portfolio through Expanded R&D Team : - -
Immuno-suppressants Limited Competition products Backward integration of IF/DF
-
An <.>» R?G Company
19
Re-Design to State-of-Art, EU/TGA approved Plant with Enhanced Capacity
L
~c:; LIFE SCIENCES
Infrastructure & Backend Capabilities
An <.>» R?G Company
20
L
~c:; LIFE SCIENCES
Manufacturing Facilities
Formulations Unit 1, Ankleshwar
Formulations Unit 2, Ankleshwar
API Unit, Navi Mumbai
F1 unit caters to the domestic and emerging markets
• • Multipurpose plant with dedicated product lines for oral dosage forms including tablets,
liquids and powder
• WHO, Kenya, Nigeria approved
F2 unit caters to the regulated markets
• • Dedicated product lines for oral dosage (capsules & tablets) • • WHO, EUGMP (from Hamburg Health authority), Canada, Ethiopia, Kenya, Sudan,
Equipped to handle low RH and low temperature conditions products
Nigeria approved
• MF1: Multipurpose unit catering to emerging markets including India • MF2: Dedicated immunosuppressant facility catering to regulated and emerging markets
including India
• MF3: Multipurpose unit catering to regulated and emerging markets including India • WHO, TGA Australia approved & Written Confirmation (WC) received from CDSCO
An <.>» R?G Company
21
~c:; LIFE SCIENCES
Strong Backend Capabilities
Quality
• All critical SOPs harmonized through CQA • Quarterly internal audit of all plants by CQA • All critical deviations, change controls and market
complaints investigation approved by CQA
Regulatory
• Well established & evolved Regulatory function catering to Canada, UK, EU, Australia and emerging markets Expertise of eCTD submissions Integrated project management activities
• •
•
Formulations R&D In addition to Formulations Development of IR, have capabilities to develop modified release & complex generics
• Dossiers gap analysis and fulfilment • Tech transfer/site transfer activities • GLP compliant analytical lab for Development and
Validation of Analytical Methods
Digitalisation Focus Areas
• Quality Management systems : e-QMS, e-DMS, e-LMS. • Access to critical manufacturing equipment through IRIS
scanner
• All QC instruments attached with dedicated software
and server
• All stability chambers with software control •
Secondary packing Complies with EUFMD requirement for Track and Trace.
An <.>» R?G Company
22
L
~c:; LIFE SCIENCES
Operational Highlights
An <.>» R?G Company
23
L
~c:; LIFE SCIENCES
Top 10 Operational Highlights
1
2
3
4
5
6
7
8
9
Comprehensive Life Cycle Management Strategy for DF Legacy products yielding results
Legacy Product Naprosyn becomes the first 50 Cr+ Brand of the Company
New Product portfolio across identified segments contributing healthy double-digit growth
::===========================================::::: ~===========================~
The New Product Denosumab Sales ~5 Cr in the very first year of Launch
New Therapy – Rheumatology becoming formidable
The New Rheumatology Franchise grows to contributing significantly to Specialty Sales
Multiple Initiatives expanding Prescriber & Patient base
Medico Marketing Pyramid | Digital Marketing Pyramid | Disease Education
Revenue/Cost optimization projects driving results
Digitalisation & Innovation Agenda impacting key areas
Revenue Enhancement: New Products, Customers and Markets| Cost Optimization: Strict Opex Control, Digitalization and AVD
“RPGServ” 3.0 grows to 9 versions; Technology upgrades| eQMS, eDMS, eLMS for product Quality
Factories, R&D, Regulatory modernising up to support Frontend
Key Products Inhouse transfer| Modernization of both plants under execution | New Products development - WIP
Increasing Industry Interface and Performance Recognition
4 Industry Awards| Increased Traction in Investor meets and Media Interaction| RPG Best Corporate Performance award
“Happiness” Initiatives driving Happy Performance focused Culture
Happiness Score increase from 83% (FY21) ➔ 84% (FY22) ➔ 87% (FY23) I Ranked #2 amongst RPG group companies
10
Headwinds Management
Diligent Management of Input Costs Increase
~c:; LIFE SCIENCES
Digitalization Initiatives: Sales and Marketing
Game Changer Customer Connect Initiative
Gen AI for Superior Customer Service & Impactful Marketing
Anytime, Anywhere Doctor Support Initiative
~ Melanicyte transfer surgery for Stable vitiligo
0
,•
,-.
Industry First Initiative
Salesforce Excellence Initiatives
~
2.0
Digital Platform -Salesforce Operations #Customer visits, customer engagement activities, sales performance analytics etc
IJ
"
•
Range of Services
E rica
HR Chatbot for quick resolution of queries related to HR process and company policies
0
•
A digital platform for Salesforce Grievance Redressal
>80000 Doctors Onboarded
An <.>» R?G Company
All above represent Illustrative list of the initiatives
25
Crowdsourcing of Ideas from Field Force
L
~c:; LIFE SCIENCES
Digitalization Initiatives: Manufacturing and Quality Operations Roadmap of >20 Initiatives under various stages of Implementation
Digital Retina Scanner
• Biometric Access with IRIS/ Retina Scanner enables consistency of electronic records and signatures
• Access to only
qualified professionals, Batch Management, Recipe Management, Au dit logs
Intelligent Chilling Plant Manager
IOT based AHU monitoring system
Power Management System
• Implementation of Utility Asset Management Systems with access over IoT, supported by Customized Algorithms for Efficient Monitoring, Control & Analytics
• Operates Pumps
•
& Chillers according to Operating Hours to maintain equal run time
• Automatically change over Working pump to Standby if Pump fails during operation
Safe, reliable, efficient, and compliant operation of electrical distribution systems, and connected assets enabling at all times
Quality Functions
e-QMS: Digital platform to track all 6 quality parameters
e-DMS: Digital platform to manage manufacturing/quality documents
e-LMS: Digital platform to track training sessions on CGMP
An <.>» R?G Company
~c:; LIFE SCIENCES
People Initiatives: Building Happy Performance focussed Culture
I Feel Valued
You Excel. We Applaud. Motivation continuum
I Live a Purposeful & Balanced Life
RPGLS Values Champions Living organizational values
An <.>» R?G Company
I Love My Work
RPGLS Heroes Outperformance recognition
High Happiness Quotient improving YoY
I Feel Connected
RPGLS Happiness Forums Leadership Connect – Month & Quarter
27
I am Growing
We Skill. You Grow. Competency building continuum
• • 0
Akanksha Career development
I cherish our Culture
RPGLS Parivar Tyohar-Utsav Shrankhla Digital RPGLS family get- together
L
~c:; LIFE SCIENCES
People Initiatives: Building Happy Performance focussed Culture- Glimpses
Rewards & Recognition: Hi-Ftire.- Function
An <.>» R?G Company
Employee Motivation: Happy Cards illTllll !:mailers
•• V
u.., U·••w,tluJalfuft. f-,r th,, bl .,n~ """ i rrjr ChaNir'l:af ,t _J.7jaln f,.,,- PM'. 1 ,u,,cnd11~l• tlJ.'
1w 5:.,-rc,,.! My I~ -ani ri,, \!l" I
lie, Y,wiJ
..L- ~c:; LIFE SCIENCES
People Initiatives: Building Happy Performance focussed Culture- Glimpses Hello Happiness Forums: Monthly Townhall for Connect, Recognition and Camaraderie
For Your Happ."ness @ R?G L I FE SCIENCES
1
•
hello happiness
RPGLS Happiness Forum
0
Monthly Town hall for Connect, Recognition and Camaraderie
hello happiness Forum
RPGLS Parivar - A Happy Parivar
An <.>» R?G Company
L
~c:; LIFE SCIENCES
People Initiatives: Building Happy Performance focussed Culture- Glimpses Parivar Tyohar Utsav Shrankhla: Virtual Celebration of Festivals with Families
For Your Happiness @ R?G L I FE SCIENCES
3
RPGLS Parivar Tyohar-Utsav Shrankhla
•
0 hello happiness
'II f -- ~- .. tf ~ -f- ;:1(.
~
I , _, -- ....-.~ '
'
II -~
;t.; _ ;:i:~ ,
-
r
I
, __,:;; -
'
"I loved these unique digital RPGLS- family get - togethers as these enabled entire RPGLS Parivaar to reach our colleagues' homes, cities, and societies across the country and celebtate with their families ... Ganapali, Diwali, Hvli, Govinda, Onam, Eid, Christmas . all our festivals; hundreds of our family members joined from their own homes and had fun.'!"
An <.>» R?G Company
L
~c:; LIFE SCIENCES
Awards & Recognitions
An <.>» R?G Company
31
L
~c:; LIFE SCIENCES
RPG Life Sciences Awarded with ‘Jamnalal Bajaj Award for Fair Business Practices’
Jamnalal Bajaj Award for Fair Business Practices (2021-22)
An <.>» R?G Company
L
~c:; LIFE SCIENCES
RPG Life Sciences Bagged Top Awards from IDMA
Industry Recognition to RPG Life Sciences
Best Patent Award
Best Corporate Citizen Award
An <.>» R?G Company
L
~c:; LIFE SCIENCES
New Launch Naprosyn+ bags Brand Champion of the Year Award
Naprosyn+
An <.>» R?G Company
L
~c:; LIFE SCIENCES
We are Committed to our Transformation Agenda to continue our upward growth trajectory
Revenue Growth
Profit Growth and Focus on Cashflows
Strong Governance
Building Domestic Formulations Business via the identified 5 Pillars
Building Global Business through New Products/Markets/Customers
Formulations and API plants Modernization and Capacity expansion
Continued diligent thrust on cost control measures both in Opex and COGS
All operations within the Framework of strong Corporate Governance
Product Re-engineering
R&D Pipeline in identified niche areas
Process Efficiencies
New Opportunities : M&A
An <.>» R?G Company
L
~c:; LIFE SCIENCES
The Journey Ahead: Diligent work on-going on 7 Pillars to “Scale-up” business
7 Pillars Identified
1
2
3
4
5
6
7
State-of-art
PLANTS
Targeted Niche- focus R&D PIPELINE
Institutionalized INNOVATION
TECHNOLOGY enablement
M&As
Lead Therapy ADJACENT Spaces
Talent Development /Acquisition
• Modern,
Cost-efficient; cGMP Compliant; EU/PICS/TGA etc approved
• Higher
Capacity ~2X
• Focused New Product Grid across 3 segments
• R&D
Organisation strengthening
• Institutionalizat
• Technology
• M&A
ion of Innovation – Idea platforms, Rewards, Reviews
Identification and adoption
• All Areas –
Front-end, Back- end Functions
• Innovation
project(s) by each Department
Framework with criteria defined - Target Therapies, Brands Margin
• Identify & explore Adjacencies in RPGLS Strength therapies
An <.>» R?G Company
• Org structure review & role/skill-gaps identification
• Talent
Development
• Talent
Acquisition in role/Skill-gaps
L
~c:; LIFE SCIENCES
T H A N K
••••• •••
Y O U
An <.>» R?G Company ________ Ri>G L1FEsc1ENcEs
L